3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
37
Terminated
10
Recruiting
8
Active not recruiting
4
Withdrawn
1
Unknown
1
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
217
Lymphoid
103
Myeloid
41
Plasma cell
25
Classical hematology
11
Sarcoma
8
Dermatologic
6
CNS
6
Genitourinary
4
Other neoplasm
3
Thoracic
2
Other
2
Gynecologic
2
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
1841
Triple Negative Breast Neoplasms
122
Neoplasms
73
Ovarian Neoplasms
55
Neoplasm Metastasis
55
Prostatic Neoplasms
52
Colorectal Neoplasms
52
Lung Neoplasms
50
Stomach Neoplasms
43
Pancreatic Neoplasms
41
Colonic Neoplasms
41
Motor Activity
39
Lymphedema
34
Breast Cancer Female
32
Carcinoma, Non-Small-Cell Lung
31
Advanced Breast Cancer
31
Melanoma
27
Endometrial Neoplasms
27
Head and Neck Neoplasms
25
Cardiotoxicity
25
Breast Diseases
25
HER2-positive Breast Cancer
22
Brain Neoplasms
21
Uterine Cervical Neoplasms
20
Fatigue
20
Breast Cancer Lymphedema
20
Pain
19
Breast Neoplasms, Male
19
Urinary Bladder Neoplasms
17
Esophageal Neoplasms
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia
×
Breast
×
Clear all
NCT05227898
2022-10-25
RESTORE
Blue Note Therapeutics
Phase NA
Unknown
352 enrolled